[ad_1]
HYDERABAD: Pharma major Aurobindo Pharma Ltd on Wednesday said its wholly owned subsidiary, Auro Vaccines Pvt Ltd, has entered into a licence agreement with Hilleman Laboratories Singapore Pte Ltd to develop, manufacture and commercialise a paediatric pentavalent vaccine candidate.
Auro Vaccines will be making milestone payments to the Singapore-based company upon achieving certain development and clinical study outcomes, Aurobindo Pharma said in a regulatory filing.
Aurobindo also said its subsidiary will also be paying royalties to Hilleman once the vaccine candidate is commercialised.
The Hyderabad-based pharma company also pointed out that the inking of the licence agreement will not have significant impact on Aurobindo Pharma, its subsidiaries or financials.
“Please note that Auro Vaccines Private Limited is not a material subsidiary to the company and the aforesaid entry into a licence agreement is not a material event. In the event of any significant impact in future, we will keep the exchanges informed about the same and provide necessary disclosures,” Aurobindo Pharma said.
Auro Vaccines will be making milestone payments to the Singapore-based company upon achieving certain development and clinical study outcomes, Aurobindo Pharma said in a regulatory filing.
Aurobindo also said its subsidiary will also be paying royalties to Hilleman once the vaccine candidate is commercialised.
The Hyderabad-based pharma company also pointed out that the inking of the licence agreement will not have significant impact on Aurobindo Pharma, its subsidiaries or financials.
“Please note that Auro Vaccines Private Limited is not a material subsidiary to the company and the aforesaid entry into a licence agreement is not a material event. In the event of any significant impact in future, we will keep the exchanges informed about the same and provide necessary disclosures,” Aurobindo Pharma said.
[ad_2]
Source link